Alimera Sciences Cancels IPO

Published: Apr 09, 2009

Private Equity Hub -- Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, has withdrawn registration for a $75 million IPO, due to “current public market conditions.” It had planned to trade on the Nasdaq, with Credit Suisse and Citi serving as co-lead underwriters.

Back to news